MEDP Medpace Holdings, Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1668397 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.4%
TTM net income YoY19.6%
TTM EPS YoY25.9%
Revenue 3-yr CAGR16.8%
Net income 3-yr CAGR23.8%
Margins
Gross margin—
Operating margin21.4%
Net margin18.2%
FCF margin23.5%
EBITDA margin22.3%
Returns
ROE117.9%
ROA25.5%
ROIC (approx.)—
Asset turnover1.40x
Leverage & solvency
Liabilities / assets74.6%
Debt / equity0.00x
Current ratio0.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.40x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.53B | $2.11B |
| SG&A expense | $197.56M | $180.18M |
| Operating income | $534.93M | $446.87M |
| Pretax income | $542.38M | $475.92M |
| Income tax | $91.25M | $71.54M |
| Net income | $451.12M | $404.39M |
| EBITDA | $562.11M | $474.68M |
| EPS (basic) | 15.64 | 13.06 |
| EPS (diluted) | 15.28 | 12.63 |
| Weighted avg. shares (diluted) | 29.53M | 32.01M |
| Balance sheet | ||
| Cash & equivalents | $497.05M | $669.44M |
| Receivables | $402.08M | $296.44M |
| Current assets | $989.62M | $1.03B |
| PP&E, net | $131.06M | $123.61M |
| Goodwill | $662.40M | $662.40M |
| Intangibles | $33.42M | $34.37M |
| Total assets | $1.98B | $2.10B |
| Current liabilities | $1.34B | $1.10B |
| Total liabilities | $1.52B | $1.28B |
| Shareholders' equity | $459.07M | $825.54M |
| Shares outstanding | 28.37M | 30.63M |
| Cash flow statement | ||
| Operating cash flow | $713.22M | $608.82M |
| Capital expenditure | $31.36M | $36.55M |
| Free cash flow | $681.87M | $572.27M |
| Investing cash flow | -$31.14M | -$28.31M |
| Financing cash flow | -$860.39M | -$154.01M |
| Depreciation & amortization | $27.18M | $27.81M |
| Stock-based compensation | $34.79M | $25.51M |
| Share buybacks | $917.39M | $169.87M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.